5.85

1.74% 0.10

After Hours: 5.75 -0.10 -1.71%

Satellos Bioscience Inc (MSLE)

Overview News Price History Discussions Forecast

Satellos Bioscience Inc stock is traded at $5.85, with a volume of 18,817. It is up +1.74% in the last 24 hours and down -16.55% over the past month. Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.

Previous Close:

$5.75

Open:

$5.75

24h Volume:

18,817

Relative Volume:

0.29

Market Cap:

$121.86M

Revenue:

Net Income/Loss:

$-28.50M

P/E Ratio:

-3.2271

EPS:

-1.8128

Net Cash Flow:

$-25.87M

1W Performance:

-0.51%

1M Performance:

-16.55%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1-Day Range:

$5.72

$5.85

1-Week Range:

$5.61

$6.10

52-Week Range:

$5.50

$13.39

Satellos Bioscience Inc Stock (MSLE) Company Profile

Name

Satellos Bioscience Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

Address

Employee

Twitter

Next Earnings Date

2026-05-19

Latest SEC Filings

MSLE's Discussions on Twitter

Compare MSLE vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MSLE Satellos Bioscience Inc	5.85	119.78M	0	-28.50M	-25.87M	-1.8128
VRTX Vertex Pharmaceuticals Inc	458.99	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	607.93	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	892.26	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	282.72	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	157.77	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Satellos Bioscience Inc Stock (MSLE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-06-26	Initiated	Leerink Partners	Outperform
Mar-11-26	Initiated	Cantor Fitzgerald	Overweight

Satellos Bioscience Inc Stock (MSLE) Latest News

Jun 14, 2026

MSLE Q1 2026 Earnings: Smaller-than-Expected Loss as Positive EPS Surprise Drives Focus on Drug Development ProgressEarnings Cycle Report - newsline.com

Jun 14, 2026

Jun 13, 2026

Satellos Bioscience (MSLE) Slips 2.54% as Stock Tests Key Support Near $5.46Dividend Arbitrage - newsline.com

Jun 13, 2026

Jun 11, 2026

Why Satellos Bioscience Inc. stock is sliding today - Wealth Awesome

Jun 11, 2026

Satellos Bioscience Q1 2026 Earnings: Narrower-Than-Expected Loss as DMD Program AdvancesProfit Cycle Analysis - newsline.com

Jun 11, 2026

Jun 09, 2026

Satellos Bioscience (MSCL) Investor Relations, Earnings Summary & Outlook - Quartr

Jun 03, 2026

Leerink initiates Satellos Bioscience stock with Outperform rating - Investing.com

Jun 03, 2026

Jun 02, 2026

MSLE Q1 2026 Earnings: Narrower-Than-Expected Net Loss Highlights Cost Discipline Amid Pre-Revenue StatusForward EPS Estimate - newsline.com

Jun 02, 2026

May 27, 2026

Satellos Bioscience (MSLE) Surges 9%: Volume Spike Tests Key Resistance ZoneMESA MA - The Legal Advocate

May 27, 2026

Satellos to Participate in Upcoming Investor Conferences - Investing News Network

May 27, 2026

Satellos Bioscience to Highlight Neuromuscular Pipeline at June Investor Conferences - TipRanks

May 27, 2026

Satellos Bioscience (NASDAQ: MSLE) to present SAT-3247 program at June investor conferences - Stock Titan

May 27, 2026

Satellos Bioscience (MSLE) Surges 7% as Biotech Stock Breaks Above Key SupportBearish Pattern Stocks - newsline.com

May 27, 2026

May 25, 2026

Satellos Bioscience (MSLE) Slides 5.5% as Biotech Sector Headwinds Weigh on SentimentHidden Order - Newser

May 25, 2026

May 24, 2026

Satellos Bioscience Q1 2026 Earnings: Narrower Loss Reported, Stock Slips on Lack of Revenue Progress - Newser

May 24, 2026

May 22, 2026